In our research group we have published reports on mucosal transcript levels of tumor necrosis factor (TNF) as a biomarker for response to and when to stop anti-TNF thereapy [19–21], However, most of the studies are of retrospective design and there is a lack of validated studies of prognostic biomarkers to predict the clinical outcome in IBD with high reliability. This evidence concerns the gene TNF and inflammatory bowel disease.